Köse, DuyguYüksel, Tuğba NurcanHalıcı, ZekaiÇadırcı, ElifGürbüz, Muhammed Ali2022-05-112022-05-1120211308-8742https://doi.org/10.5152/eurasianjmed.2021.20342https://hdl.handle.net/20.500.11776/9106Objective: We designed an experimental model of sepsis in rats to investigate the effects of agomelatine (AGO) on lung tissues using molecular and histopathological methods. Materials and Methods: In our experimental model, the 32 rats were divided into 4 groups: group 1: control group (HEALTHY); group 2: lipopolysaccharide group (LPS); group 3: LPS plus 50 mg/kg AGO group (LPS + AGO50); and group 4: LPS plus 100 mg/kg AGO group (LPS + AGO100). An LPS-induced sepsis model was performed to replicate the pathology of sepsis. Rats from all 4 groups were killed after 12 hours, and their lungs were quickly collected. To investigate the therapeutic strategy, we evaluated tumor necrosis factoralpha (TNF-alpha) and nuclear factor-kappa B (NF-kappa B) messenger RNA expressions by real-time polymerase chain reaction using molecular methods and lung tissue damage indicators using histopathological methods. Results: The expressions of TNF-alpha and NF-kappa B were reduced in the groups treated with AGO. The histopathology results supported the molecular results. Conclusion: In this experimental study, we demonstrated for the first time the positive effects of AGO on LPS-induced sepsis in lung tissue using molecular and histopathological methods, indicating that it contributes to the prevention of lung damage.en10.5152/eurasianjmed.2021.20342info:eu-repo/semantics/openAccessSepsisagomelatinetumor necrosis factor-alphanuclear factor-kappa BMelatonin ReceptorAnimal-ModelsMt2 ReceptorsSepsisGenesArticle532127131N/AWOS:0006603111000112-s2.0-8510850872034177296Q3